---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-025156"
form_type: "8-K"
ticker: "ABT"
cik: "0000001800"
company_name: "ABBOTT LABORATORIES"
filed_at: "2023-07-20T23:59:59+00:00"
generated_at: "2026-06-13T05:43:32.399031+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Abbott Q2 2023: Sales $10B, adjusted EPS $1.08; underlying base organic growth 11.5%

## Summary
- Q2 GAAP diluted EPS $0.78; adjusted diluted EPS $1.08; revenue $9,978M, down 11.4% reported (COVID testing decline).
- Underlying base business organic sales growth 11.5% led by Medical Devices (+14.2% organic) and Nutrition (+9.9% organic).
- Full-year 2023 adjusted EPS guidance reaffirmed at $4.30-$4.50; COVID testing sales forecast $1.3B.
- FreeStyle Libre sales $1.3B, up 24.7% organic; new product approvals: TactiFlex, AVEIR dual-chamber pacemaker.
- Quarterly dividend $0.51/share declared, payable Aug 15, 2023; 51 consecutive years of increases.

## SEC filing metadata
- accession: 0001628280-23-025156
- form_type: 8-K
- ticker: ABT
- cik: 0000001800
- company_name: ABBOTT LABORATORIES
- filed_at: 2023-07-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800/000162828023025156/0001628280-23-025156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800/000162828023025156/abt-20230720.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-025156
- JSON: https://secwatch.observer/filing/0001628280-23-025156.json
- Plain text: https://secwatch.observer/filing/0001628280-23-025156.txt

## Key facts
- Earnings Releases
  ABBOTT LABORATORIES reported second quarter 2023 results: revenue $10.0 billion, EPS $0.78.
  - Period: second quarter 2023
  - Revenue: $10.0 billion
  - EPS: $0.78
  - Result: reported results
  source text: in accordance with GAAP. --- EX-99.1 (EX-99.1) --- 9.1 News Release Abbott Reports Second-Quarter 2023 Results; Increases Outlook For Underlying Base Business – Sales of $10.0 billion driven by strong underlying base business performance – Reported sales decreased 11.4 percent due to anticipated decline in COVID-19 testing-related sales versus prior year –
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800/000162828023025156/0001628280-23-025156-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.